MARKET

OMER

OMER

Omeros
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.670
-0.230
-7.93%
Closed 16:00 05/24 EDT
OPEN
2.840
PREV CLOSE
2.900
HIGH
2.890
LOW
2.510
VOLUME
1.75M
TURNOVER
2.65M
52 WEEK HIGH
16.62
52 WEEK LOW
2.500
MARKET CAP
167.49M
P/E (TTM)
-0.8516
1D
5D
1M
3M
1Y
5Y
Omeros stock rises 7% after beating Q1 earnings estimate
Omeros (NASDAQ:OMER +7.9%) stock rose after the company posted better than-expected Q1 earnings, helped by royalties from ophthalmic product Omidria. Net loss for the quarter was $33M or $0.53 per share
Seekingalpha · 05/11 16:27
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million.
Benzinga · 05/11 16:25
Omeros: Q1 Earnings Insights
Omeros (NASDAQ:OMER) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros beat estimated earnings by 25.35%, reporting an EPS of $-0.53 versus an estimate of $-0.7...
Benzinga · 05/10 21:00
Omeros Q1 EPS $(0.53) Beats $(0.71) Estimate
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.71) by 25.35 percent. This is a 7.02 percent increase over losses of $(0.57) per share from the same
Benzinga · 05/10 20:36
Omeros Q1 2022 Earnings Preview
Omeros (NASDAQ:OMER) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$0.69 and the consensus Revenue Estimate is $0M Over
Seekingalpha · 05/09 21:35
Omeros Earnings Preview
Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Omeros will report an earnings per share (EPS) of $-0.71.
Benzinga · 05/09 18:08
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 211 companies set new 52-week lows.
Benzinga · 05/03 16:20
Omeros Highlights Journal Of Clinical Oncology Publication Detailing Pivotal Trial Results For Narsoplimab In HSCT-TMA
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ:OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment
Benzinga · 04/20 12:46
More
No Data
Learn about the latest financial forecast of OMER. Analyze the recent business situations of Omeros through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
37.50%Buy
25.00%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average OMER stock price target is 31.20 with a high estimate of 100.00 and a low estimate of 12.00.
High100.00
Average31.20
Low12.00
Current 2.670
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 176
Institutional Holdings: 31.18M
% Owned: 49.71%
Shares Outstanding: 62.73M
TypeInstitutionsShares
Increased
34
858.38K
New
16
863.10K
Decreased
47
2.79M
Sold Out
24
741.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
Gregory Demopulos
Chief Accounting Officer/Vice President - Finance/Treasurer
Michael Jacobsen
Chief Scientific Officer/Vice President
George Gaitanaris
Vice President/General Counsel/Secretary
Peter Cancelmo
Vice President/Director of Human Resources
Peter Williams
Vice President
Christopher Bral
Vice President
Nadia Dac
Vice President
Bruce Meiklejohn
Vice President
Catherine Melfi
Vice President
Tina Quinton
Vice President
J. Steven Whitaker
Vice President - Business Development
Timothy Duffy
Lead Director/Independent Director
Thomas Cable
Director
Peter Demopulos
Independent Director
Thomas Bumol
Independent Director
Arnold Hanish
Independent Director
Leroy Hood
Independent Director
Rajiv Shah
Independent Director
Kurt Zumwalt
No Data
No Data
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.